GlassScriptPhysician profile
Kimy Charani
NPI 1467412874
$20,722.77
in general payments reported to CMS, 2019-2025
43 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,047 · 2020: $1,591 · 2021: $3,139 · 2022: $2,171 · 2023: $5,904 · 2024: $2,043 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,274 · Honoraria: $2,500 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,274.32 |
| Honoraria | $2,500.00 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $7,925.83 | 2019-2025 | Seglentis, Zoryve |
| Astrazeneca Pharmaceuticals LP | $2,520.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,846.91 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $1,031.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $986.76 | 2019-2025 | |
| Novo Nordisk INC | $818.60 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $765.24 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $579.90 | 2019-2024 | Xarelto, Spravato |
| Amgen INC. | $543.37 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.47 | 2019-2025 | Jardiance, Spiriva, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.42 | 2019-2024 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $254.61 | 2022-2024 | Ajovy, Austedo Xr |
| Merck Sharp & Dohme LLC | $254.47 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Sumitomo Pharma America, INC. | $236.02 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $198.37 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimy Charani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.